Bridgewater Associates slashed a stake in Apple, halved its Lilly investment, doubled down on Microsoft, and bought Moderna ...
Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...